(Q42239583)

19 October 2017

title

Optimum timing of oseltamivir: lessons from Bangladesh (English)

1 reference

19 October 2017

0 references

1 reference

Michael G Ison

1

1 reference

19 October 2017

publication date

22 November 2013

1 reference

Lancet Infectious Diseases

19 October 2017

published in

1 reference

19 October 2017

volume

14

1 reference

19 October 2017

issue

2

1 reference

19 October 2017

page(s)

88-89

1 reference

Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Clinical use of approved influenza antivirals: therapy and prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Oseltamivir dosing for influenza infection in premature neonates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Oral oseltamivir treatment of influenza in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Early administration of oral oseltamivir increases the benefits of influenza treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Strengthening observational evidence for antiviral effectiveness in influenza A (H5N1).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Outcomes of adults hospitalised with severe influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970287-1

7 January 2021

10.1016/S1473-3099(13)70287-1

Identifiers

DOI

1 reference

19 October 2017

1 reference